435 related articles for article (PubMed ID: 14681681)
1. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.
Kumar R; Angelini S; Hemminki K
Oncogene; 2003 Dec; 22(58):9217-24. PubMed ID: 14681681
[TBL] [Abstract][Full Text] [Related]
2. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
[TBL] [Abstract][Full Text] [Related]
3. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.
Omholt K; Karsberg S; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2002 Nov; 8(11):3468-74. PubMed ID: 12429636
[TBL] [Abstract][Full Text] [Related]
4. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.
Fujimoto A; Morita R; Hatta N; Takehara K; Takata M
Oncogene; 1999 Apr; 18(15):2527-32. PubMed ID: 10229204
[TBL] [Abstract][Full Text] [Related]
5. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis.
Demunter A; Ahmadian MR; Libbrecht L; Stas M; Baens M; Scheffzek K; Degreef H; De Wolf-Peeters C; van Den Oord JJ
Cancer Res; 2001 Jun; 61(12):4916-22. PubMed ID: 11406571
[TBL] [Abstract][Full Text] [Related]
6. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
Pollock PM; Welch J; Hayward NK
Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
[TBL] [Abstract][Full Text] [Related]
7. Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation.
Popović Hadzija M; Radosevic S; Kovacević D; Lukac J; Hadzija M; Spaventi R; Pavelić K; Kapitanović S
Mutat Res; 2004 Apr; 548(1-2):61-73. PubMed ID: 15063137
[TBL] [Abstract][Full Text] [Related]
8. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.
Zerp SF; van Elsas A; Peltenburg LT; Schrier PI
Br J Cancer; 1999 Feb; 79(5-6):921-6. PubMed ID: 10070891
[TBL] [Abstract][Full Text] [Related]
9. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform.
Lilleberg SL; Durocher J; Sanders C; Walters K; Culver K
Ann N Y Acad Sci; 2004 Jun; 1022():250-6. PubMed ID: 15251969
[TBL] [Abstract][Full Text] [Related]
10. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
12. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the role of the ras protooncogene point mutation in human uveal melanomas.
Soparker CN; O'Brien JM; Albert DM
Invest Ophthalmol Vis Sci; 1993 Jun; 34(7):2203-9. PubMed ID: 8505202
[TBL] [Abstract][Full Text] [Related]
14. [Analysis, identification and correction of some errors of model refseqs appeared in NCBI Human Gene Database by in silico cloning and experimental verification of novel human genes].
Zhang DL; Ji L; Li YD
Yi Chuan Xue Bao; 2004 May; 31(5):431-43. PubMed ID: 15478601
[TBL] [Abstract][Full Text] [Related]
15. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
16. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
17. p53 and RAS gene mutations in multiple myeloma.
Portier M; Molès JP; Mazars GR; Jeanteur P; Bataille R; Klein B; Theillet C
Oncogene; 1992 Dec; 7(12):2539-43. PubMed ID: 1461658
[TBL] [Abstract][Full Text] [Related]
18. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing.
Knowles MA; Williamson M
Cancer Res; 1993 Jan; 53(1):133-9. PubMed ID: 8093230
[TBL] [Abstract][Full Text] [Related]
19. CDKN2A mutation and deletion status in thin and thick primary melanoma.
Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ
Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity in the MXI1 gene is a frequent occurrence in melanoma.
Ariyanayagam-Baksh SM; Baksh FK; Swalsky PA; Finkelstein SD
Mod Pathol; 2003 Oct; 16(10):992-5. PubMed ID: 14559981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]